Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. Central Drugs Standard Control Organisation (CDSCO) has issued a public notice under the Drugs and Cosmetics Act, 1940 and Cosmetics Rules, 2020, prohibiting use of cosmetics as injectable preparations by consumers, professionals, or aesthetic clinics. The notice flags four key violations: use of GNRAS or prohibited ingredients per BIS standards, misleading or false labelling claims, tampering with manufacturer inscriptions, and use of cosmetics for treatment purposes beyond their statutory scope of cleansing, beautifying, promoting attractiveness, or altering appearance.
Source: shortlink.uk/1vo9D

2. The Karnataka High Court has stayed criminal proceedings in a case involving the alleged sale of pirated books on an e-commerce marketplace, with the platform arguing that it functions solely as an intermediary and does not directly control third-party seller listings. The development brings renewed focus to intermediary liability and the extent of safe harbour protections available to e-commerce platforms under Indian laws.
Source: shortlink.uk/1vo9I

3. The High Court of Himachal Pradesh has quashed criminal proceedings against a pharma unit initiated by a Central drug inspector, holding that prosecution for manufacture, sale and distribution of drugs lies with State authorities and not the Central Government. The ruling clarifies the limits of enforcement powers of central drug regulator and may affect similar cases initiated by CDSCO against pharmaceutical manufacturers.
Source: shortlink.uk/1q0Oz

4. The Central Drugs Standard Control Organisation has reportedly initiated a review of concerns raised by retail chemists over the functioning of electronic pharmacies. Following assurances from the regulator, several state pharmacy associations have declined to participate in the proposed nationwide strike to avoid disruption in the supply of essential medicines and protect patient interests.
Source: shortlink.uk/1vo9S

5. A US federal jury found a major pharmaceutical company liable for delaying a generic version of a blockbuster constipation drug through an anticompetitive “pay-for-delay” arrangement. The verdict awarded nearly USD 885 million in damages and heightened scrutiny of delayed generic entry practices. The ruling may increase antitrust, litigation, and compliance risks for pharmaceutical companies globally.
Source: shortlink.uk/1q0OM

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. Central Drugs Standard Control Organisation (CDSCO) has rejected a cosmetics import registration certificate and barred the importer from seeking fresh registrations for one year over alleged submission of fabricated documents under the Cosmetics Rules, 2020. The move underscores stricter regulatory scrutiny and tougher enforcement of compliance standards in India’s cosmetics import sector.
Source: shortlink.uk/1vfpf

2. India’s Punjab and Haryana High Court has upheld the conviction of a clinic owner under the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act 1994, observing that lapses in maintaining mandatory records, including Form ‘F’, cannot be treated as minor procedural defects. The Court emphasized that proper documentation is central to enforcement of the PCPNDT framework aimed at preventing female foeticide and preserving regulatory oversight of diagnostic practices. This is important as the ruling reinforces strict compliance expectations for clinics, diagnostic centres, and healthcare establishments operating under the PCPNDT regime. The judgment signals that deficiencies in statutory records may attract penal consequences even where procedural irregularities in inspection or search are alleged.
Source: shortlink.uk/1vfr5

3. Parliamentary Standing Committee has reportedly recommended expansion of Regional Raw Drug Repositories under the National Medicinal Plants Board, particularly in biodiversity-rich regions, to support documentation, authentication, conservation, and sustainable utilisation of medicinal plants used in Ayush systems. The recommendation reflects continued policy attention toward strengthening medicinal plant infrastructure and raw material quality within the herbal and phytopharmaceutical ecosystem.
Source: shortlink.uk/1pTkP

4. The Central Consumer Protection Authority (CCPA) of India has launched a probe into the online sale of an allegedly unregistered herbicide on major e-commerce platforms, citing concerns over regulatory non-compliance and inadequate product disclosures. The action underscores rising scrutiny of hazardous products sold online and may push platforms to strengthen seller verification and compliance mechanisms.
Source: shortlink.uk/1vfpx

5. The Bombay High Court held that although infringement relief was unavailable in the “OCTRIDE” and “OTIDE” dispute due to both marks being registered, passing off protection could still be granted under common law. The Court cited the marks phonetic similarity, the Plaintiff’s prior goodwill and market reputation, and the heightened risk of confusion in pharmaceutical products.
Source: shortlink.uk/1pTl0

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Central Drugs Standard Control Organization (CDSCO) has cancelled the import registration certificate of a cosmetic peel product due to non-compliance with prescribed pH tolerance limits and labelling requirements, including a “patient use” claim that did not conform to applicable Indian cosmetic labelling standards. The action reflects increased regulatory scrutiny of cosmetic product safety and labelling in India.
Source: shortlink.uk/1uZtd

2. A Parliamentary panel has recommended that the Central Drugs Standard Control Organisation (CDSCO) establish a uniform regulatory framework to address misleading advertisements relating to Ayush products, noting that the existing mechanism may result in inconsistent handling of complaints across States. The panel further observed that the absence of a standardized timeline and monitoring framework for disposal of complaints could undermine the effectiveness of the complaint reporting mechanism and potentially discourage citizens from reporting such violations.
Source: shortlink.uk/1uZth

3. The Ministry of Electronics and Information Technology has launched the Intellectual Property Catalyst initiative and digital platform to accelerate commercialization of innovations in electronics and information technology. The initiative will support patent filing, technology transfer, licensing, and industry collaboration, while enabling startups and enterprises to access indigenous technologies developed through publicly funded research.
Source: shortlink.uk/1pDUl

4. The Indian government is reportedly considering measures to regulate rising healthcare costs in private hospitals, including capping doctor consultation fees and hospital billing margins through amendments to the Clinical Establishments Act, 2010. The move aims to standardize private healthcare costs, enhance transparency, and prevent overcharging, while balancing regulatory oversight with professional autonomy in medical practice.
Source: shortlink.uk/1uZtk

5. The US Food and Drug Administration (USFDA) is reportedly exploring regulatory pathways to support the repurposing of older approved drugs for new therapeutic indications, with the aim of accelerating patient access to treatments while reducing development timelines and costs. USFDA said it is focusing on three categories of drug candidates: those with existing data supporting new uses, those showing early clinical promise, and those backed by preclinical or AI/ML-generated findings. FDA is seeking public input from patients, clinicians, public health officials, and researchers regarding priority disease areas and potential drugs for repurposing.
Source: shortlink.uk/1pDUo